Jingyu Zhong

Jingyu Zhong

Auto-generated profile, based on publicly available information

Jingyu Zhong

Department of Imaging, Tongren Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2022 in European Radiology
Verified
Journal Article
Closed access
PDF file
JZJingyu Zhong
Jingyu Zhong
CZChengxiu Zhang
Chengxiu Zhang
YHYangfan Hu
Yangfan Hu
JZJing Zhang
Jing Zhang
YLYun Liu
Yun Liu
WYWeiwu Yao
Weiwu Yao


20 August 2022 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
JZJingyu Zhong
Jingyu Zhong
YHYangfan Hu
Yangfan Hu
GZGuangcheng Zhang
Guangcheng Zhang
YXYue Xing
Yue Xing
DDDefang Ding
Defang Ding
WYWeiwu Yao
Weiwu Yao
Objective: To update the systematic review of radiomics in osteosarcoma. Methods: PubMed, Embase, Web of Science, China National Knowledge Infrastructure, and Wanfang Data were searched to identify articles on osteosarcoma radiomics until May 15, 2022. The studies were assessed by Radiomics Quality Score (RQS), Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement, Checklist for Artificial Intelligence in Medical Imaging (CLAIM), and modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. The evidence supporting radiomics application for osteosarcoma was rated according to meta-analysis results. Results: Twenty-nine articles were included. The average of the ideal percentage of RQS, the TRIPOD adherence rate and the CLAIM adherence rate were 29.2%, 59.2%, and 63.7%, respectively. RQS identified a radiomics-specific issue of phantom study. TRIPOD addressed deficiency in blindness of assessment. CLAIM and TRIPOD both pointed out shortness in missing data handling and sample size or power calculation. CLAIM identified extra disadvantages in data de-identification and failure analysis. External validation and open science were emphasized by all the above three tools. The risk of bias and applicability concerns were mainly related to the index test. The meta-analysis of radiomics predicting neoadjuvant chemotherapy response by MRI presented a diagnostic odds ratio (95% confidence interval) of 28.83 (10.27–80.95) on testing datasets and was rated as weak evidence. Conclusions: The quality of osteosarcoma radiomics studies is insufficient. More investigation is needed before using radiomics to optimize osteosarcoma treatment. CLAIM is recommended to guide the design and reporting of radiomics research.

20 August 2022 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
JZJingyu Zhong
Jingyu Zhong
YHYangfan Hu
Yangfan Hu
YXYue Xing
Yue Xing
XGXiang Ge
Xiang Ge
DDDefang Ding
Defang Ding
WYWeiwu Yao
Weiwu Yao
Background: Multiple tools have been applied to radiomics evaluation, while evidence rating tools for this field are still lacking. This study aims to assess the quality of pancreatitis radiomics research and test the feasibility of the evidence level rating tool. Results: Thirty studies were included after a systematic search of pancreatitis radiomics studies until February 28, 2022, via five databases. Twenty-four studies employed radiomics for diagnostic purposes. The mean ± standard deviation of the adherence rate was 38.3 ± 13.3%, 61.3 ± 11.9%, and 37.1 ± 27.2% for the Radiomics Quality Score (RQS), the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) checklist, and the Image Biomarker Standardization Initiative (IBSI) guideline for preprocessing steps, respectively. The median (range) of RQS was 7.0 (− 3.0 to 18.0). The risk of bias and application concerns were mainly related to the index test according to the modified Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. The meta-analysis on differential diagnosis of autoimmune pancreatitis versus pancreatic cancer by CT and mass-forming pancreatitis versus pancreatic cancer by MRI showed diagnostic odds ratios (95% confidence intervals) of, respectively, 189.63 (79.65–451.48) and 135.70 (36.17–509.13), both rated as weak evidence mainly due to the insufficient sample size. Conclusions: More research on prognosis of acute pancreatitis is encouraged. The current pancreatitis radiomics studies have insufficient quality and share common scientific disadvantages. The evidence level rating is feasible and necessary for bringing the field of radiomics from preclinical research area to clinical stage.

9 January 2025 in European Radiology
Verified
Journal Article
Open access
PDF file
JZJingyu Zhong
Jingyu Zhong
XLXianwei Liu
Xianwei Liu
JLJunjie Lu
Junjie Lu
JYJiarui Yang
Jiarui Yang
GZGuangcheng Zhang
Guangcheng Zhang
WYWeiwu Yao
Weiwu Yao
Objectives: To investigate how studies determine the sample size when developing radiomics prediction models for binary outcomes, and whether the sample size meets the estimates obtained by using established criteria. Methods: We identified radiomics studies that were published from 01 January 2023 to 31 December 2023 in seven leading peer-reviewed radiological journals. We reviewed the sample size justification methods, and actual sample size used. We calculated and compared the actual sample size used to the estimates obtained by using three established criteria proposed by Riley et al. We investigated which characteristics factors were associated with the sufficient sample size that meets the estimates obtained by using established criteria proposed by Riley et al. Results: We included 116 studies. Eleven out of one hundred sixteen studies justified the sample size, in which 6/11 performed a priori sample size calculation. The median (first and third quartile, Q1, Q3) of the total sample size is 223 (130, 463), and those of sample size for training are 150 (90, 288). The median (Q1, Q3) difference between total sample size and minimum sample size according to established criteria are −100 (−216, 183), and those differences between total sample size and a more restrictive approach based on established criteria are −268 (−427, −157). The presence of external testing and the specialty of the topic were associated with sufficient sample size. Conclusion: Radiomics studies are often designed without sample size justification, whose sample size may be too small to avoid overfitting. Sample size justification is encouraged when developing a radiomics model. Key Points: Question Sample size justification is critical to help minimize overfitting in developing a radiomics model, but is overlooked and underpowered in radiomics research. Findings Few of the radiomics models justified, calculated, or reported their sample size, and most of them did not meet the recent formal sample size criteria. Clinical relevance Radiomics models are often designed without sample size justification. Consequently, many models are too small to avoid overfitting. It should be encouraged to justify, perform, and report the considerations on sample size when developing radiomics models.

29 January 2020 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
JZJingyu Zhong
Jingyu Zhong
LSLiping Si
Liping Si
JGJia Geng
Jia Geng
YXYue Xing
Yue Xing
YHYangfan Hu
Yangfan Hu
WYWeiwu Yao
Weiwu Yao
Background: Chondromyxoid fibroma-like osteosarcoma (CMF-OS) is an exceedingly rare subtype of low-grade central osteosarcoma (LGCO), accounting for up to 10% of cases and making it difficult to diagnose. CMF-OS is frequently misdiagnosed on a radiological examination and biopsy, even after the initial operation. Its treatment is a controversial issue due to its low-grade classification and actual high-grade behavior. Case presentation: We retrospectively reviewed the medical charts of more than 2000 osteosarcoma patients between 2008 and 2019; 11 patients with CMF-OS were identified, of which six patients were treated by our institution with complete clinical characteristics, including treatment and prognosis, radiological and pathological features were reviewed. Three males and three females with a median age of 46 (range 22–56) years were pathologically proven to have CMF-OS. The radiological presentation of CMF-OS is variable, thus radiological misdiagnoses are common. However, one must not ignore a malignant radiologic appearance. The most distinctive pathological feature conferring the diagnosis of CMF-OS is the presence of osteoid production directly by the tumor cells under a chondromyxoid fibroma (CMF)-like background. Differential diagnoses based on comprehensive data from CMF, LGCO, chondrosarcoma (CHS), conventional osteosarcoma (COS), etc., are needed. All patients were treated with an operation and chemotherapy, and one patient received additional radiotherapy. Nevertheless, recurrence and metastasis are common in CMF-OS patients. Relatively invasive biological behavior of CMF-OS is against the low-grade classification of this disease. Conclusions: It is important to recognize CMF-OS and distinguish it from CMF, CHS, COS and other LGCOs. CMF-OS has a relatively poor prognosis despite its low-grade classification.